Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Tvardi's STAT3 inhibitor flunks IPF trial amid high dropout rate
The biotech reported high dropout rates and placebolike efficacy in a phase 2 trial of its idiopathic pulmonary fibrosis prospect.
Nick Paul Taylor
Oct 13, 2025 9:25am
Gilead, Arcus keep TIGIT dream alive with 27-month OS data
Oct 13, 2025 7:05am
Moderna posts melanoma data behind decision to say 'I do' to IDO
Oct 13, 2025 5:15am
Regeneron shares updated data on hearing loss gene therapy
Oct 12, 2025 10:18am
Cabaletta's CAR-T wipes out B cells with no preconditioning
Oct 10, 2025 11:11am
Ono's BMS-partnered IO drug passes phase 2 gastric cancer test
Oct 9, 2025 10:10am
